Spero Therapeutics Announces Third Quarter 2024 Operating

1 day ago · Third quarter 2024 Financial Results . Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September …

CouponFollow Extension

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating

1 week from now

1 day ago · Third quarter 2024 Financial Results . Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September …

globenewswire.com

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating

1 week from now

Third quarter 2024 Financial Results . Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September 30, 2024, …

nasdaq.com

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating

1 week from now

1 day ago · Third quarter 2024 Financial Results . Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September …

biospace.com

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating …

1 week from now

1 day ago · Third quarter 2024 Financial Results . Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September …

businessinsider.com

$17
OFF

Spero Therapeutics Announces Second Quarter 2024 Operating …

1 week from now

Jun 30, 2024 · Spero reported a net loss of $17.9 million, or ($0.33) per share of common stock, basic and diluted, for the second quarter ended June 30, 2024, compared with a net loss of …

morningstar.com

$12
OFF

Spero Therapeutics Announces First Quarter 2024 Operating

1 week from now

May 15, 2024 · Spero reported a net loss of $12.7 million, or ($0.24) per share of common stock, basic and diluted, for the first quarter ended March 31, 2024, compared with a net loss of …

globenewswire.com

$76
OFF

Spero Therapeutics : Announces Third Quarter 2024 Operating …

1 week from now

2 days ago · As of September 30, 2024, Spero had cash and cash equivalents of $76.3 million. Following the reduction in force and restructuring described above, Spero estimates that its …

marketscreener.com

$63
OFF

Spero Therapeutics Announces Second Quarter 2024 Operating …

1 week from now

Aug 5, 2024 · As of June 30, 2024, Spero had cash and cash equivalents of $63.5 million. Based on its current operating plans, Spero expects that its cash and cash equivalents, together with …

marketscreener.com

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating …

1 week from now

1 day ago · Spero Therapeutics (SPRO) reported Q3 2024 financial results with a net loss of $17.1 million ($0.32 per share), compared to $3.2 million loss in Q3 2023. Revenue decreased …

stocktitan.net

$17
OFF

Spero Therapeutics Announces Second Quarter 2024 Operating

1 week from now

Aug 5, 2024 · Spero reported a net loss of $17.9 million, or ($0.33) per share of common stock, basic and diluted, for the second quarter ended June 30, 2024, compared with a net loss of …

globenewswire.com

$8
OFF

Mersana Therapeutics Provides Business Update And Announces …

1 week from now

Sep 30, 2024 · Net cash used in operating activities for the third quarter of 2024 was $8.6 million, which reflects the impact of the aforementioned $8 million milestone payment and a $3.5 …

nasdaq.com

$30
OFF

2024-11-14 | Omega Therapeutics Announces Successful …

1 week from now

2 days ago · Third Quarter 2024 Financial Results. As of September 30, 2024, the Company had cash and cash equivalents totaling $30.4 million, which is expected to fund operations into Q2 …

stockhouse.com

$6
OFF

Atossa Therapeutics Announces Third Quarter 2024 ... - Morningstar

1 week from now

4 days ago · Total operating expenses were $6.4 million and $20.5 million for the three and nine months ended September 30, 2024 which was a decrease of $1.1 million and $1.9 million, …

morningstar.com

$76
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating

1 week from now

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, …

advfn.com

FAQs about Spero Therapeutics Announces Third Quarter 2024 Operating Coupon?

How did Spero Therapeutics (Spro) perform in the quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) reported earnings for the last quarter on August 10th. The company posted earnings per share (EPS) of ($0.23), which was $0.06 better than the consensus estimate of ($0.29). Spero Therapeutics had revenue of $2.72 million for the quarter, exceeding the consensus estimate of $2.20 million. ...

How much did Spero lose in the first quarter?

Spero reported a net loss of $12.7 million, or ($0.24) per share of common stock, basic and diluted, for the first quarter ended March 31, 2024, compared with a net loss of $13.3 million, or ($0.25) per share of common stock, basic and diluted, for the first quarter ended March 31, 2023. ...

Should I buy Spero Therapeutics stock at $37?

Raghuram Selvaraju of H.C. Wainwright maintains a Buy rating on Spero Therapeutics (NASDAQ: SPRO) stock, but lowered the price target to $37 from $43. ...

How many research reports have been made about Spero Therapeutics?

In the past 90 days, only 1 research report has been made about Spero Therapeutics. Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. ...

How much money does Spero Therapeutics make a year?

Spero Therapeutics (NASDAQ:SPRO) generates $53.51 million in revenue each year and earns $-46,420,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. ...

Where is Spero Therapeutics headquartered?

Spero Therapeutics is headquartered at 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at (857) 242-1600 or via email at [email protected]. ...